Phase I/II Study of Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Teriflunomide (Primary)
- Indications Tropical spastic paraparesis
- Focus Pharmacodynamics
- 09 Jan 2023 Planned number of patients changed from 16 to 24.
- 06 Jan 2023 Planned End Date changed from 30 Jun 2024 to 31 Aug 2025.
- 06 Jan 2023 Planned primary completion date changed from 30 Jun 2024 to 31 Aug 2025.